Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B

Table 11 Correlation between change of fibrotic stages before and after treatment, liver function and serum fibrotic markers before treatment in IFN-γ group

Items	Improved (n = 9)	Unchanged (n = 12)	Deteriorated (n = 9)
Albumin (g/L)	39.9 ± 5.0	40.8 ± 4.6	40.6 ± 6.7
Globulin (g/L)	28.1 ± 4.6	30.7 ± 4.0	31.9 ± 5.3
ALT activities (U)	94 ± 56	79 ± 51	171 ± 286
AST activities (U)	77 ± 53	56 ± 33	80 ± 73
GGT activities (U)	76 ± 41	76 ± 48	81 ± 40
Total bilirubin (mmol)	13.4 ± 7.6	16.5 ± 6.4	18.9 ± 7.0
Direct bilirubin (mmol)	3.0 ± 2.2	3.6 ± 2.5	3.3 ± 2.0
HA (μg/L)	219 ± 230	284 ± 246	237 ± 145
LM (μg/L)	97 ± 34	87 ± 18	102 ± 30
IV-C (μg/L)	128 ± 84	104 ± 56	92 ± 32
PIIIP (μg/L)	12.0 ± 6.2	9.1 ± 5.5	10.9 ± 2.3